SCHEMBL140930

SCHEMBL140930

Cc1ccc(S(=O)(=O)OCP(=O)(O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 1/20 0.47
STAT3 P40763 2/20 0.44
GAA P10253 2/20 0.42
MMP1 P03956 2/20 0.41
MMP9 P14780 2/20 0.41
MMP8 P22894 2/20 0.41
MMP13 P45452 2/20 0.41
MMP3 P08254 1/20 0.41
MMP7 P09237 1/20 0.41
MMP14 P50281 1/20 0.41
F2 P00734 2/20 0.41
PRSS1 P07477 2/20 0.41
PRSS2 P07478 2/20 0.41
PRSS3 P35030 2/20 0.41
ALDH1A1 P00352 4/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL15941687 0.95 MMP2 (0.44) MMP2CA12CA9CA14STAT3
Pyridine SCHEMBL156519 0.88 STAT3 (0.40) MMP2CA12CA9CA14STAT3
SCHEMBL23581205 0.88 MMP2 (0.46) MMP2CA12CA9STAT3GAA
SCHEMBL140943 0.88 STAT3 (0.43) MMP2CA12CA9CA14STAT3
SCHEMBL14390991 0.85 STAT3 (0.42) MMP2CA12CA9CA14STAT3
SCHEMBL23703227 0.84 GAA (0.43) CA12CA9STAT3GAAALDH1A1
SCHEMBL4206461 0.82 STAT3 (0.40) MMP2CA12CA9CA14STAT3
SCHEMBL140173 0.82 GAA (0.42) CA12CA9STAT3GAAALDH1A1
SCHEMBL3149080 0.82 CA2 (0.47) MMP2CA12CA9CA14GAA
SCHEMBL28512466 0.81 CA12 (0.44) MMP2CA12CA9CA14GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974921-A Method for synthesizing tenofovir 浙江嘉化新材料有限公司 2023-04-18 CN claimed
CN-115181148-A Compound with anti-tumor effect based on cordycepin through derivatization 南京工业大学 2022-10-14 CN claimed
CN-108178772-B Preparation method of tenofovir disoproxil fumarate intermediate 上海博悦生物科技有限公司 2020-01-21 CN claimed
EP-2682397-B1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same GILEAD SCIENCES INC (US) 2017-04-19 EP claimed
WO-2015051874-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ZENTIVA, K.S. (CZ) 2015-04-16 WO claimed
EP-2860185-A1 An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof Zentiva, k.s. (CZ) 2015-04-15 EP claimed
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof CHIMERIX, INC. (US) 2014-02-13 US claimed
EP-2682397-A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same GILEAD SCIENCES, INC. (US) 2014-01-08 EP claimed
JP-4651264-B2 2011-03-16 JP claimed
WO-2006003295-A1 METHOD FOR HYDROXYMETHYLATION OF A PHOSPHONIC ACID IN AN ESTERIFIED FORM RHODIA CHIMIE (FR) 2006-01-12 WO claimed
EP-1301519-A2 PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME GILEAD SCIENCES, INC. (US) 2003-04-16 EP claimed
US-20020119443-A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same GILEAD SCIENCES, INC. 2002-08-29 US claimed
WO-2002008241-A2 PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME GILEAD SCIENCES, INC. (US) 2002-01-31 WO claimed
EP-0654037-B1 ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS ACAD OF SCIENCE CZECH REPUBLIC (CZ) 1999-05-12 EP claimed
EP-0654037-A1 ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1995-05-24 EP claimed
WO-1994003467-A2 ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1994-02-17 WO claimed
EP-0206459-B1 9-(PHOSPHONYLMETHOXYALKYL) ADENINES, METHOD FOR THEIR PREPARATION AND THEIR USE Ceskoslovenska akademie ved (CS) 1992-07-15 EP claimed
EP-0253412-B1 N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY Ceskoslovenska akademie ved (CS) 1990-10-31 EP claimed
EP-0253412-A2 N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity Ceskoslovenska akademie ved (CS) 1988-01-20 EP claimed
EP-0206459-A2 9-(Phosphonylmethoxyalkyl) adenines, method for their preparation and their use Ceskoslovenska akademie ved (CS) 1986-12-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof PHOSPHO1, PIK3CA, PNP MMP2 3084/4885CA12 1841/4885CA9 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.